TWI765917B - 用於治療眼疾的方法 - Google Patents

用於治療眼疾的方法 Download PDF

Info

Publication number
TWI765917B
TWI765917B TW106133818A TW106133818A TWI765917B TW I765917 B TWI765917 B TW I765917B TW 106133818 A TW106133818 A TW 106133818A TW 106133818 A TW106133818 A TW 106133818A TW I765917 B TWI765917 B TW I765917B
Authority
TW
Taiwan
Prior art keywords
eye
diabetic
bmx
compound
cells
Prior art date
Application number
TW106133818A
Other languages
English (en)
Chinese (zh)
Other versions
TW201828933A (zh
Inventor
春億 邱
陳嘉南
Original Assignee
彥臣生技藥品股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 彥臣生技藥品股份有限公司 filed Critical 彥臣生技藥品股份有限公司
Publication of TW201828933A publication Critical patent/TW201828933A/zh
Application granted granted Critical
Publication of TWI765917B publication Critical patent/TWI765917B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW106133818A 2016-09-29 2017-09-29 用於治療眼疾的方法 TWI765917B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662401725P 2016-09-29 2016-09-29
US62/401,725 2016-09-29

Publications (2)

Publication Number Publication Date
TW201828933A TW201828933A (zh) 2018-08-16
TWI765917B true TWI765917B (zh) 2022-06-01

Family

ID=61688114

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106133818A TWI765917B (zh) 2016-09-29 2017-09-29 用於治療眼疾的方法

Country Status (9)

Country Link
US (1) US11045435B2 (enExample)
EP (1) EP3518913B1 (enExample)
JP (3) JP2019531296A (enExample)
KR (1) KR102341446B1 (enExample)
CN (1) CN109789115A (enExample)
CA (1) CA3038845C (enExample)
MY (1) MY198731A (enExample)
TW (1) TWI765917B (enExample)
WO (1) WO2018059543A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585196B (zh) * 2018-06-13 2022-11-04 郭涛 一种治疗及预防眼科疾病的药物及其应用
BR112023024812A2 (pt) * 2021-05-28 2024-02-20 Novelwise Pharmaceutical Corp Combinação e método para tratar um câncer resistente à temozolomida, método para um tratamento pessoal de precisão para um câncer resistente a fármacos, e, uso da combinação

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256401A1 (en) * 2009-04-03 2010-10-07 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2504460A1 (en) * 2002-11-12 2004-05-27 Peter G. Klimko Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
JP4873904B2 (ja) * 2005-08-22 2012-02-08 国立大学法人弘前大学 眼血管血流障害改善剤
US20100056522A1 (en) 2007-03-28 2010-03-04 Santen Pharmaceutical Co., Ltd. Intraocular pressure-lowering agent comprising compound having histone deacetylase inhibitor effect as active ingredient
CA2630174A1 (en) * 2007-05-02 2008-11-02 Mitchell Alan Winnik Loading quantum dots into thermo-responsive microgels by reversible transfer from organic solvents to water
EP2259771A1 (en) 2008-03-03 2010-12-15 Pharmalight Inc. Stimulation of ocular retrobulbar flow using ocular irritants
PT2346827E (pt) * 2008-08-27 2014-02-17 Leo Pharma As Derivados de piridina como inibidores de receptor vegfr-2 e proteína tirosina quinase
EP2236503B1 (en) * 2009-04-03 2014-02-26 NatureWise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
EP2277387B1 (en) * 2009-07-22 2016-10-19 NatureWise Biotech & Medicals Corporation New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly
ES2820855T3 (es) * 2011-05-09 2021-04-22 Allegro Pharmaceuticals Llc Antagonistas del receptor de integrina y sus métodos de uso
CA2946086A1 (en) 2014-04-17 2015-10-22 Teraclon Idf, S.L. Recombinant monoclonal antibodies vnar neutralizing the vascular endothelial growth factor (vegf)
US9956254B2 (en) * 2015-02-26 2018-05-01 Naturewise Biotech & Medicals Corporation Extract of taiwanese propolis for treating ocular diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100256401A1 (en) * 2009-04-03 2010-10-07 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Expert Opinion on Investigational Drugs, Volume 18, 2009 - Issue 5 Pages 637-646 Published online: 24 Apr 2009 *
PLoS ONE 8(11): e81592. doi:10.1371/journal.pone.0081592, Nov 27, 2013; *

Also Published As

Publication number Publication date
MY198731A (en) 2023-09-20
WO2018059543A1 (en) 2018-04-05
EP3518913B1 (en) 2025-07-23
US20180085329A1 (en) 2018-03-29
EP3518913A4 (en) 2020-05-27
US11045435B2 (en) 2021-06-29
JP2021138710A (ja) 2021-09-16
EP3518913A1 (en) 2019-08-07
KR20190045304A (ko) 2019-05-02
CA3038845A1 (en) 2018-04-05
JP2023116748A (ja) 2023-08-22
JP2019531296A (ja) 2019-10-31
TW201828933A (zh) 2018-08-16
EP3518913C0 (en) 2025-07-23
CA3038845C (en) 2022-04-19
KR102341446B1 (ko) 2021-12-21
CN109789115A (zh) 2019-05-21

Similar Documents

Publication Publication Date Title
Wang et al. Melatonin ameliorates oxidative stress-mediated injuries through induction of HO-1 and restores autophagic flux in dry eye
Liang et al. Salidroside alleviates oxidative stress in dry eye disease by activating autophagy through AMPK-Sirt1 pathway
Wang et al. Erythropoietin protects retinal pigment epithelial cells from oxidative damage
Fu et al. Neuroprotective effect of apigenin against hypoxic-ischemic brain injury in neonatal rats via activation of the PI3K/Akt/Nrf2 signaling pathway
Cao et al. Protection of the retinal ganglion cells: intravitreal injection of resveratrol in mouse model of ocular hypertension
Hombrebueno et al. Intravitreal injection of normal saline induces retinal degeneration in the C57BL/6J mouse
JP2023116748A (ja) 眼疾患の処置方法
Zhang et al. Expression of aquaporin 4 and Kir4. 1 in diabetic rat retina: treatment with minocycline
Li et al. Micelles based on polyvinylpyrrolidone VA64: A potential nanoplatform for the ocular delivery of apocynin
Albalawi et al. Immunomodulatory effects of Kaempferol on microglial and Macrophage cells during the progression of diabetic retinopathy
JP6874075B2 (ja) 眼疾患を治療するためのタイワンプロポリス抽出物
HK1212225A1 (en) Therapeutic formulation and methods of treatment
Chen et al. Polyphenol-Based Self-Assembled Nanoparticles Treating Uveitis by Inflammation-Oxidative Stress Suppression
IT202300003891A1 (it) Utilizzo di miriocina come adiuvante nella chirurgia del glaucoma
Kaldırım et al. Efficacy of hyperbaric oxygen therapy on central corneal thickness, intraocular pressure, and nerve fiber layer in patients with type 2 diabetes: A prospective cohort study
Mei et al. Linarin ameliorates innate inflammatory response in an experimental dry eye model via modulation of the NLRP3 inflammasome
CN103239472A (zh) 褐藻多糖硫酸酯的药物新用途
Zhang et al. Tetrahedral Framework Nucleic Acid‐Based Delivery of DJ‐1‐saRNA Prevent Retinal Ischaemia–Reperfusion Injury via Inhibiting Ferroptosis
HK40002019A (en) Methods for treating ocular diseases
Hu et al. MDL800, a SIRT6 activator, mitigates neuroinflammation-induced retinal damage by modulating microglial M1/M2 polarization in experimental glaucoma
Chen et al. Vitamin K1 Alleviates Retinal Inflammation Following Acute Ocular Hypertension by Modulating Microglial Ferroptosis
TWI587858B (zh) 亞丁基苯酞之應用
KR102068697B1 (ko) 염증성 안구표면질환의 예방 또는 치료용 조성물
JP6386713B2 (ja) 脳循環障害の予防剤および／または治療剤
Wang et al. Delayed progression of diabetic cataractogenesis and retinopathy by topical administration of highly biocompatible carbon dots derived from Scutellaria barbata and Herba hedyotis diffusae